|
Uwe Meya is a board-qualified neurologist and psychiatrist by background with an impressive track record in pharmaceutical research and development, focused on disorders of the central nervous system (CNS). His experience spans multiple CNS indications and covers the full spectrum of drug development from first-in-man through to regulatory filing.
He was most recently head of research portfolio management for Roche in Basel, where he contributed to the global strategic direction of all therapeutic areas. While at Roche and Novartis, he worked on several of the compounds subsequently out-licensed to Synosia and received the Roche Global Development Leadership Reward in recognition of his effectiveness in building relationships and partnerships.
Prior to joining Roche in Basel, Uwe was with Novartis where he managed a team of researchers in CNS clinical development and later served as a member of a special clinical development management team, overseeing projects from late pre-clinical studies through to the end of Phase I. He previously worked at Ciba-Geigy, Knoll and Schering in CNS research.
Uwe was educated in Germany and studied medicine in Aachen, Germany and Glasgow, Scotland. He received his medical degree from the University of Aachen, where he also completed a doctorate in psychiatry.
He is a member of the European College of Neuropsychopharmacology and is a founding member of the International College of Geriatric Psychoneuropharmacology, where he served as a council member for more than three years. | 